Verona Pharma announces departure of Chief Medical Officer

Kenneth Newman

Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for respiratory diseases, announces that Kenneth Newman, M.D., has resigned from his position as Chief Medical Officer, effective from 30 April 2018, to pursue other opportunities. The Company has commenced an executive search for a replacement.

Jan-Anders Karlsson, PhD, CEO of Verona Pharma, commented, “We thank Ken for his outstanding service and many contributions to the Company. Over the past three years, he has led the acceleration of RPL554’s clinical development program into Phase 2b trials and overseen seven successful clinical trials. He played an instrumental role in establishing our U.S. presence and we wish him the best in his future endeavors.”

Companies